IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Revenue of IDEAYA Biosciences, Inc. (IDYA)
Revenue in 2023 (TTM): $23.39 M
According to IDEAYA Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $23.39 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of IDEAYA Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $23.39 M | $19.38 M | $-130,421,000 | $-112,961,000 | $-112,961,000 |
| 2022 | $50.93 M | $48.83 M | $-62,502,000 | $-58,655,000 | $-54,808,000 |
| 2021 | $27.94 M | $26.22 M | $-50,268,000 | $-49,762,000 | $-47,531,000 |
| 2020 | $19.54 M | $-20,160,000 | $-35,344,000 | $-34,495,000 | $-32,265,000 |
| 2019 | $ | $-1,245,000 | $-44,271,000 | $-41,975,000 | $-38,442,000 |
| 2018 | $ | $-886,000 | $-35,531,000 | $-34,346,000 | $-34,346,000 |
| 2017 | $ | $-391,000 | $-14,047,000 | $-11,862,000 | $-11,862,000 |